BOC Sciences provides comprehensive high throughput screening (HTS) libraries designed to accelerate hit discovery across diverse therapeutic programs. Our collections span bioactive compounds, drug repurposing sets, natural products, and fully custom-synthesized libraries — each built with rigorous cheminformatics-driven design, validated by NMR and HPLC, and delivered in screening-ready formats. From library design through hit confirmation, we support every stage of your screening workflow with scientific expertise and responsive project management.
High throughput screening libraries are systematically curated collections of chemical compounds formatted for rapid, automated evaluation against biological targets. In modern hit identification, an HTS campaign can test tens of thousands to millions of compounds in parallel, using microplate-based assay formats and robotic liquid handling to detect molecules that modulate a target of interest. The quality of an HTS library directly shapes screening outcomes — structural diversity, drug-like physicochemical profiles, and the absence of assay-interfering compounds all determine whether a campaign yields tractable chemical starting points or wasted screening effort. At BOC Sciences, our HTS libraries encompass over 1.6 million small molecules spanning 5,000 distinct scaffolds and more than 300 potential therapeutic targets, providing the breadth and depth needed to discover novel hit series across therapeutic areas.
Our activity-based libraries contain compounds with experimentally validated biological activity against well-characterized targets and signaling pathways. These collections are ideal for phenotypic screening, pathway deconvolution, and drug repurposing studies where prior biological knowledge accelerates hit interpretation.
Drug repurposing libraries contain approved drugs, clinical-stage candidates, and preclinical tool compounds with established safety and pharmacokinetic profiles. Screening these collections enables rapid identification of new therapeutic indications for existing molecules.
Natural products and their derivatives occupy a privileged region of chemical space that has been evolutionarily selected for biological activity. Our collections include purified compounds from microbial, plant, and marine sources, as well as semi-synthetic analogs.
When off-the-shelf libraries do not match your target's requirements, BOC Sciences designs and synthesizes fully customized compound libraries. Our custom libraries are built from your target hypothesis, scaffold preference, or pharmacophore model using parallel synthesis and combinatorial chemistry.
BOC Sciences helps research teams move from screening objectives to library design, compound selection, formatting, quality verification, and screening-ready delivery — with full cheminformatics and analytical support at every step.
BOC Sciences supports multiple experimental screening platforms selected according to the target type, assay model, required data depth, and screening objective.
| Screening Platform | Test Indicators and Supported Applications |
| Biochemical High-Throughput Screening | Enzyme activity, receptor binding, protein interactions, substrate conversion, and concentration-dependent responses can be measured in purified target systems. These assays support target-based screening, modulator discovery, binding confirmation, and hit prioritization. |
| Cell-Based High-Throughput Screening | Cellular responses are evaluated through indicators such as viability, proliferation, apoptosis, reporter activity, and pathway signaling. The resulting data support functional screening, cellular hit confirmation, cytotoxicity assessment, and pathway modulator discovery. |
| Image-Based High-Content Screening | Automated imaging and quantitative analysis reveal changes in cell morphology, protein localization, organelle structure, signal translocation, and multiparametric single-cell phenotypes. This approach supports phenotypic profiling, complex cell model screening, mechanism studies, and detailed hit validation. |
| Microarray-Based Screening | Parallel microarray analysis measures binding intensity, interaction specificity, competitive binding, and molecular recognition patterns across numerous samples. Applications include small-molecule and antibody screening, antigen evaluation, target profiling, and biomarker discovery. |
Tell us whether your project uses a biochemical, cell-based, imaging, or microarray readout. We will align compound selection, concentration, solvent, plate layout, controls, quality checks, and data fields with the experimental workflow.
BOC Sciences begins each project with a structured consultation to review your biological target, assay format, throughput requirements, hit-finding goals, and downstream medicinal chemistry strategy. This stage defines library scope — compound count, diversity metrics, physicochemical filters, and any target-class-specific enrichment criteria — ensuring the delivered library integrates seamlessly with your screening infrastructure.
Using cheminformatics-driven selection algorithms, our team filters and prioritizes compounds based on molecular weight, logP, hydrogen bond donors/acceptors, TPSA, rotatable bond count, and Fsp3. For target-focused libraries, we incorporate pharmacophore similarity, docking scores, or machine-learning predictions. A diversity analysis report confirms scaffold representation and chemical space coverage before compound preparation begins.
Selected compounds are retrieved, dissolved to standardized concentrations in a solvent system matched to your screening platform, and arrayed into plates according to your specified layout. Each plate includes positive and negative control wells. QC samples are drawn from each batch for LC-MS purity verification. Plates are barcode-labeled, heat-sealed under inert atmosphere, and stored at controlled conditions until shipment.
Libraries are shipped with detailed documentation including certificate of analysis, plate map files, compound structure data (SD files or SMILES), and physicochemical property tables. Post-screening, we provide hit list review, cheminformatics analysis, and rapid resupply of confirmed hits. We also offer iterative library refinement — using screening results to design follow-up focused libraries around confirmed hit scaffolds.
Many in-house screening collections suffer from historical accumulation bias — over-representation of certain chemotypes from legacy projects and under-representation of novel scaffolds. BOC Sciences addresses this by applying scaffold diversity algorithms that maximize chemical space coverage while maintaining drug-like property constraints. Our libraries are continually refreshed with newly synthesized compounds that explore underrepresented regions of biologically relevant chemical space, ensuring your screens discover novel chemical starting points rather than re-identifying known pharmacophores.
Redundant compounds — multiple close analogs of the same scaffold — inflate library size without proportionally increasing the probability of finding diverse hit series. Our cheminformatics pipeline applies Tanimoto similarity clustering and Murcko scaffold decomposition to identify and reduce redundancy. We deliver libraries where each scaffold is represented by a defined cluster size, balancing the ability to detect preliminary SAR with the need to sample diverse chemotypes efficiently.
Compounds that aggregate, fluoresce, redox-cycle, or precipitate under assay conditions generate false positives and false negatives that waste follow-up resources. Our libraries are computationally filtered to remove known pan-assay interference compounds (PAINS) and experimentally flagged for problematic behavior in common assay formats. Solubility is assessed in aqueous buffer and DMSO stock conditions, with poorly soluble compounds either excluded or flagged with recommended maximum screening concentrations.
Mismatched plate maps, incorrect well positions, and inconsistent concentration data create data integrity problems that can derail an entire screening campaign. BOC Sciences employs a laboratory information management system that tracks every compound from source vial to destination well with full chain-of-custody documentation. Each plate is verified against its manifest by barcode scanning at multiple checkpoints, and the delivered data package includes exact well coordinates, compound identifiers, and QC results.
Collaborate with BOC Sciences to access expert library design, compound sourcing and synthesis, quality-controlled formatting, and integrated data analysis — all tailored to your drug discovery program.
Our compound resources cover diverse bioactive, repurposing, natural product, focused, and custom-synthesized collections. Libraries can be assembled from existing compounds or configured specifically for a target, pathway, scaffold class, physicochemical range, or assay format.
Integrated medicinal and synthetic chemistry support allows us to prepare missing structures, replace unavailable compounds, resupply hits, and build focused analogue series. Synthesis, purification, analytical review, and screening preparation are coordinated within the same project plan.
We support biochemical, cell-based, image-based high-content, and microarray screening formats. Library composition, plate layout, concentration, controls, and compound filters are adapted to the experimental readout and its likely interference risks.
Chemists, assay scientists, analytical specialists, data analysts, and project coordinators review connected parts of the workflow. This multidisciplinary perspective helps clients interpret weak or conflicting signals and choose appropriate confirmation, counter-screening, or analogue strategies.
Screening diverse or target-focused libraries enables research teams to test many chemical hypotheses in parallel and identify initial active compounds more efficiently. Libraries can support target-based screening, phenotypic screening, pathway analysis, assay validation, and the selection of compounds for deeper activity testing.
Screening related structures helps connect molecular changes with activity, selectivity, solubility, and cellular response. BOC Sciences can expand confirmed hits into focused analogue sets and combine screening data with structure-based drug discovery methods to guide practical design decisions.
Libraries of pharmacologically characterized compounds can reveal activity against a new target or phenotype. Existing mechanism and target annotations make results easier to interpret, prioritize, and connect with follow-up experiments while still requiring confirmation in the project-specific assay system.
Client Needs: A biotechnology company required a focused compound library for screening against a panel of disease-relevant kinases. They needed compounds with both type I and type II kinase inhibitor chemotypes, balanced hinge-binding scaffold diversity, and physicochemical properties suitable for cell-based follow-up assays.
Challenges: The client's kinase panel included targets with divergent ATP-binding site architectures, making it difficult to cover all targets with a single scaffold family. Additionally, several targets had been extensively screened by competitors, increasing the risk of re-identifying known chemotypes.
Solution: We applied pharmacophore-based filtering across our inventory to select compounds with known kinase hinge-binding motifs, then used computational docking against the client's target structures to refine the selection. Scaffold diversity algorithms ensured balanced representation across chemotype families while prioritizing underrepresented scaffolds. The final 12,000-compound library was formatted in 384-well plates at 10 mM DMSO stock concentration with full analytical QC documentation. The client achieved confirmed hit rates exceeding 2% in primary screening with clean dose-response behavior in follow-up assays.
Outcome: The client identified multiple novel hinge-binding scaffolds across their kinase panel and advanced three chemotype series into lead optimization.
Client Needs: An academic screening center developing a miniaturized 1,536-well phenotypic assay needed a diverse compound library pre-filtered for aqueous solubility. Their low-volume assay format was sensitive to compound precipitation and DMSO tolerance issues.
Challenges: The assay's 2.5 µL total volume left minimal tolerance for DMSO concentration variability or compound precipitation. Standard diversity libraries contained numerous compounds that would crash out under these conditions, threatening assay integrity and data quality.
Solution: We applied computational solubility prediction followed by experimental nephelometry screening to select compounds with demonstrated solubility above 100 µM in assay-compatible buffer. The final 8,000-compound diversity library was formatted in 1,536-well plates at optimized DMSO concentrations, with each compound's maximum recommended screening concentration annotated in the data package. Plates were verified for absence of visible precipitate after freeze-thaw cycling.
Outcome: The client completed primary screening without precipitation-related artifacts and identified multiple tractable hit clusters from diverse chemotypes for further investigation.
High-throughput screening, or HTS, combines automated liquid handling, microplate assays, sensitive detection methods, and data analysis to evaluate large compound collections efficiently. A reproducible biochemical or cell-based assay with an adequate signal window is established before compounds are tested under standardized conditions. Readouts may measure enzyme activity, molecular binding, reporter expression, pathway signaling, or cellular phenotypes. Following signal normalization and assay quality assessment, primary hits are identified for retesting, concentration-response analysis, orthogonal confirmation, and subsequent chemical or mechanistic investigation.
A suitable HTS library combines relevant chemical diversity, reliable sample information, and compatibility with the selected assay. Important design factors include scaffold distribution, molecular weight, lipophilicity, polarity, solubility, chemical reactivity, structural redundancy, and potential interference with the detection method. Target-focused projects may also benefit from known bioactive compounds, relevant pharmacophores, or selected chemical classes. Each compound should have traceable identity, concentration, storage location, and well-position data. Careful library design reduces low-value samples and improves screening efficiency, hit interpretation, and follow-up analogue selection.
Primary HTS signals may reflect genuine activity or artifacts caused by aggregation, precipitation, reactive groups, optical interference, or plate-handling variation. Confirmation commonly includes independent retesting, concentration-response analysis, counter-screens, and orthogonal assays, together with verification of compound identity and sample condition. Confirmed hits can then be prioritized according to activity, reproducibility, selectivity, structural features, analogue relationships, solubility, and interference risk. This layered evaluation helps eliminate misleading signals and identifies compounds that provide more credible starting points for mechanism studies and structure-activity relationship analysis.
Yes. BOC Sciences can design HTS libraries around the client’s target, assay principle, detection format, desired chemical space, and follow-up research objectives. Compounds may be selected from structurally diverse, bioactive, natural product, or target-focused collections, while custom synthesis can supply required scaffolds and analogue series. Selection criteria may incorporate molecular descriptors, structural similarity, scaffold coverage, solubility, reactive groups, and assay-interference risk. This approach produces a focused, assay-compatible collection rather than relying on an undifferentiated general-purpose library.
Deliverables are defined by the screening objective and project scope. They may include a selected or custom-prepared compound collection, chemical identities and structures, concentration information, plate maps, well-position records, and relevant quality review data. BOC Sciences can also support assay-compatible dispensing, microplate configuration, screening execution, data organization, hit retesting, and result interpretation. For prioritized hits, follow-up services may include compound resupply, analogue selection, custom synthesis, and structure-activity relationship studies, helping clients progress from initial screening signals to systematically evaluated compound series.
We evaluated several providers for our kinase-focused library project and found BOC Sciences offered highly competitive pricing without compromising on compound quality or documentation standards. The transparent cost breakdown for design, synthesis, and formatting made budgeting straightforward for our program.
— A Drug Discovery Project Manager in the United States
From initial consultation to library delivery, the entire process moved faster than we anticipated. The project timeline was clearly communicated at each stage, and the library arrived formatted exactly to our plate specifications — we were screening within two days of receipt.
— Principal Scientist, U.S. Academic Screening Facility
The cheminformatics support we received during library design was exceptional. Their team understood the nuances of our GPCR target class and made scaffold recommendations that we had not considered — several of which yielded our most promising hit series.
— A Senior Scientist in Biochemical Screening, United Kingdom
When we needed to troubleshoot a solubility issue with a subset of compounds, their scientific team responded within hours with experimental data and alternative compound recommendations. This level of post-delivery support made a real difference to our project timeline.
— An Assay Development Scientist in Canada
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
